KALA BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.3 USD | +1.94% |
|
-4.40% | -10.00% |
| Apr. 02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
| Mar. 29 | KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 127.5 | 380.2 | 79.26 | 60.86 | 18.85 | 17.74 | - | - |
| Enterprise Value (EV) 1 | 113.2 | 298.9 | 66.05 | -9.624 | 18.85 | 20.21 | -21.95 | -40.65 |
| P/E ratio | -1.34 x | -3.41 x | -0.55 x | -1.29 x | -0.4 x | -0.62 x | -0.55 x | -1.47 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 21 x | 59.8 x | 7.05 x | 15.6 x | - | - | - | 0.71 x |
| EV / Revenue | 18.6 x | 47 x | 5.88 x | -2.47 x | - | - | - | -1.63 x |
| EV / EBITDA | -1,462,740 x | -3,644,724 x | - | - | - | - | - | - |
| EV / FCF | -1,203,566 x | -3,226,530 x | -605,276 x | - | - | - | - | - |
| FCF Yield | -0% | -0% | -0% | - | - | - | - | - |
| Price to Book | 4.48 x | 3.55 x | 4.72 x | - | - | - | - | - |
| Nbr of stocks (in thousands) | 691 | 1,122 | 1,310 | 1,595 | 2,693 | 2,816 | - | - |
| Reference price 2 | 184.5 | 339.0 | 60.50 | 38.15 | 7.000 | 6.300 | 6.300 | 6.300 |
| Announcement Date | 2/12/20 | 2/25/21 | 3/29/22 | 3/3/23 | 3/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 6.074 | 6.362 | 11.24 | 3.892 | - | - | - | 25 |
| EBITDA | -77.39 | -82.01 | - | - | - | - | - | - |
| EBIT 1 | -88.22 | -96.23 | -130.2 | -81.71 | -39.66 | -41.6 | -38.79 | -15.37 |
| Operating Margin | -1,452.49% | -1,512.59% | -1,158.76% | -2,099.33% | - | - | - | -61.47% |
| Earnings before Tax (EBT) 1 | -94.35 | -104.3 | -142.6 | -44.82 | -42.2 | -40.24 | -42.17 | -18.7 |
| Net income 1 | -94.35 | -104.3 | -142.6 | -44.82 | -42.2 | -40.24 | -42.17 | -18.7 |
| Net margin | -1,553.29% | -1,639.85% | -1,268.73% | -1,151.64% | - | - | - | -74.81% |
| EPS 2 | -138.0 | -99.50 | -109.5 | -29.48 | -17.35 | -10.17 | -11.50 | -4.280 |
| Free Cash Flow | -94.06 | -92.64 | -109.1 | - | - | - | - | - |
| FCF margin | -1,548.49% | -1,456.08% | -970.83% | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/12/20 | 2/25/21 | 3/29/22 | 3/3/23 | 3/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.067 | 1.856 | 1.372 | 2.1 | 0.42 | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -26.07 | -46.82 | -30.91 | -25.97 | -14.57 | -10.25 | -11.68 | -9.599 | -8.762 | -9.619 | -9.9 | -9.9 | -10.9 | -10.9 |
| Operating Margin | -850.05% | -2,522.36% | -2,253.21% | -1,236.76% | -3,468.81% | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -28.13 | -47.57 | -32.94 | -28.11 | 29.07 | -12.84 | -14.46 | -10.41 | -8.704 | -8.627 | -9.38 | -9.405 | -10.43 | -10.46 |
| Net income 1 | -28.13 | -47.57 | -32.94 | -28.11 | 29.07 | -12.84 | -14.46 | -10.41 | -8.704 | -8.627 | -9.38 | -9.405 | -10.43 | -10.46 |
| Net margin | -917.09% | -2,562.93% | -2,400.95% | -1,338.62% | 6,922.14% | - | - | - | - | - | - | - | - | - |
| EPS 2 | -21.50 | -34.00 | -22.50 | -19.00 | 19.25 | -7.970 | -6.990 | -4.360 | -3.410 | -2.990 | -2.890 | -2.860 | -3.095 | -1.870 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/15/21 | 3/29/22 | 5/16/22 | 8/11/22 | 11/8/22 | 3/3/23 | 5/9/23 | 8/4/23 | 11/13/23 | 3/29/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 2.47 | - | - |
| Net Cash position 1 | 14.3 | 81.3 | 13.2 | 70.5 | - | - | 39.7 | 58.4 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -94.1 | -92.6 | -109 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | -140% | -161% | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | -50.3% | -55.5% | -54.9% | - | - | - | - | - |
| Assets 1 | 187.6 | 188 | 259.8 | - | - | - | - | - |
| Book Value Per Share | 41.10 | 95.50 | 12.80 | - | - | - | - | - |
| Cash Flow per Share | -136.0 | -86.60 | - | - | - | - | - | - |
| Capex | 1.34 | 1.94 | 0.89 | - | - | - | - | - |
| Capex / Sales | 21.98% | 30.52% | 7.88% | - | - | - | - | - |
| Announcement Date | 2/12/20 | 2/25/21 | 3/29/22 | 3/3/23 | 3/29/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
6.3
USD
Average target price
19.33
USD
Spread / Average Target
+206.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.00% | 17.74M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- KALA Stock
- Financials KALA BIO, Inc.
